Bioventus Inc. (NYSE:BVS) CFO Sells $80,317.52 in Stock

Bioventus Inc. (NYSE:BVS) CFO Mark Leonard Singleton sold 13,753 shares of Bioventus stock in a transaction on Monday, June 17th. The shares were sold at an average price of $5.84, for a total transaction of $80,317.52. Following the completion of the sale, the chief financial officer now directly owns 63,114 shares of the company’s stock, valued at approximately $368,585.76. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Mark Leonard Singleton also recently made the following trade(s):

• On Thursday, April 11th, Mark Leonard Singleton sold 4,000 shares of Bioventus stock. The stock was sold at an average price of $4.75, for a total value of $19,000.00.

Bioventus Price Performance

Shares of NYSE:BVS opened at $5.67 on Monday. The company has a market cap of $448.89 million, a price-to-earnings ratio of 16.97 and a beta of 0.89. The business has a 50 day moving average price of $5.60 and a 200 day moving average price of $5.17. The company has a quick ratio of 0.97, a current ratio of 1.53 and a debt-to-equity ratio of 1.63. Bioventus Inc. has a twelve month low of $2.70 and a twelve month high of $7.04.

Bioventus (NYSE:BVS) last posted its quarterly earnings data on Tuesday, May 7th. The company reported $0.07 earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.12. The company had revenue of $129.46 million during the quarter, compared to analysts’ expectations of $115.51 million. Bioventus had a positive return on equity of 11.91% and a negative net margin of 4.14%. Research analysts predict that Bioventus Inc. will post 0.27 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the company. Canaccord Genuity Group boosted their target price on Bioventus from $7.00 to $8.00 and gave the stock a “buy” rating in a report on Wednesday, May 8th. Craig Hallum upped their price objective on shares of Bioventus from $6.00 to $9.00 and gave the stock a “buy” rating in a report on Wednesday, March 13th.

Institutional Trading of Bioventus

A number of hedge funds have recently bought and sold shares of BVS. Acadian Asset Management LLC bought a new stake in shares of Bioventus in the 1st quarter worth approximately $28,000. Lazard Asset Management LLC bought a new stake in Bioventus in the 1st quarter valued at $40,000. SG Americas Securities LLC acquired a new position in shares of Bioventus in the 1st quarter valued at $66,000. Quadrature Capital Ltd bought a new position in shares of Bioventus during the 4th quarter worth about $85,000. Finally, GSG Advisors LLC acquired a new stake in shares of Bioventus during the 4th quarter valued at about $89,000. 62.94% of the stock is owned by institutional investors.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.